Abivax to be Added to Nasdaq Biotechnology Index PARIS, France – December 18, 2025 – 10:05 pm CET – Abivax SA (Euronext Paris: FR0012333284 – ...
Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on ...
TipRanks on MSN
Abivax price target raised to $175 from $150 at Guggenheim
Guggenheim analyst Yatin Suneja raised the firm’s price target on Abivax (ABVX) to $175 from $150 and keeps a Buy rating on the shares based on ...
Abivax SA soared about 1,300% after successful trial results for a bowel disease drug, Argenx SE was added to the elite Euro ...
French biotech company Abivax's shares rose by over 20% on Wednesday on market rumours that U.S. pharma giant Eli Lilly could ...
Abivax receives a "Strong Buy" rating, driven by positive phase 3 ABTECT induction data for obefazimod in moderate-to-severe ...
Abivax stock skyrocketed in July after the company announced overwhelmingly positive topline results from its Phase 3 ...
Abivax CEO Marc de Garidel discusses the future growth of the company, after this year's meteoric rally. Massive data breach ...
This article first appeared on GuruFocus. Abivax SA (XPAR:ABVX) is set to release its Q3 2025 earnings on Dec 15, 2025. The ...
Investing.com -- Abivax SA ADR (NASDAQ:ABVX) stock rose 2.6% in premarket trading Thursday after the clinical-stage biotechnology company announced the acceptance of 22 scientific abstracts for ...
French biotech company Abivax SA started the year with a market value of less than $500 million. After a meteoric rally, it’s now worth more than $8 billion — and some analysts see the potential for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback